https://www.dkfz.de/en/index.html

The German Cancer Research Center (Deutsches Krebsforschungs­ zentrum, DKFZ) with its more than 3,000 employees is the largest bio­ medical research institution in Germany. At DKFZ, more than 1,300 sci­ entists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.

DKFZ’s Cancer Infor­mation Service (KID) provides individual answers to all questions about cancer for patients, the general public, and health care professionals. Jointly with partners from Heidelberg University Hospital, DKFZ runs the National Center for Tumor Diseases (NCT) located in Heidelberg and Dresden, and, also in Heidelberg, the Hopp Children’s Cancer Center (KiTZ). In the German Cancer Consortium (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospi­tals with high-profile research at a Helmholtz Center at the NCT and DKTK sites is an important contribution to the endeavor of translating promising approaches from cancer research into the clinic in order to improve the chances of cancer patients.

DKFZ is a member of the Helm­holtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-WClrt­ temberg .

As a partner in this project, DKFZ intends to cooperate with the EMBL towards training of the Fellows. DKFZ can host up to one Fellow per year in the period 2020-2024 through secondments and introduce them to the ways of working, instrumentation and procedures at DKFZ. Duration of secondments will be between 2 and 6 months and will be arranged in communication with the Fellow.

Fellows who will do secondments at DKFZ will come from the field related or complementary to the field of work of DKFZ. At DKFZ Fellows will have a possibility to learn 1) in vivo manipulation of POX tumor models 2) novel DNA library preparation pro­ tocols. The Fellows will also have a chance to get acquainted with the operation novel device for in vitro induction of DNA double strand breaks. DKFZ will dedicate supervision capacity for each fellow on se­ condments.

DKFZ intends also to host mini-secondments in a duration of up to two weeks, during which Fellows will shadow operations at DKFZ